GenSight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

Sensorion Announces the Appointment of Louis J. Arcudi III as Chief Financial Officer

GenSight Biologics Reports Cash Position as of September 30, 2026

GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Redx Announces Design of ROCKETEER Phase 2 Trial for RXC008 in Fibrostenotic Crohn’s Disease 

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. 

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here. 

